Use the contrast-enhanced ultrasound in the monitoring of the effect of liver

tumors treatment by radiofrequency ablation.

Summary

High quality imaging is crucial for the treatment of liver tumors by the percutaneous

radiofrequency ablation. Imaging methods are used for planning, navigation

of the intervention and monitoring after treatment. An early detection of residual tumor

tissue or recurrence affect significantly the quality of life and life expectancy

of the patients.

Contrast enhanced ultrasound (CEUS) seems to be a suitable method

for monitoring the locoregional treatment mainly because zero radiation impact

on patient and allows the highly accurate real-time assessment of vascularization.

The aim of my work was to verify the ability of CEUS to detect residual tumor tissue

or tumor recurrence in the field of changes after radiofrequency ablation.

We evaluated the group of 73 patients, who were treated by radiofrequency ablation

(RFA) for liver cancer. CEUS reached in our group the overal sensitivity 77.27 %,

and in the group of colorectal cancer metastases 83.33 %. We compared CEUS with

results of computed tomography (CT), which is the most commonly used method

for monitoring the treatment. CEUS and CT results are similar.

Based on this study, the CEUS appears to be a suitable method for monitoring

the locoregional therapy. We have included it as a standard component of

percutaneous radiofrequency ablation.

Key words: liver, radiofrequency ablation, contrast media, ultrasonography.